GERN Geron Corporation - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 5, 2026GERN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
GERN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| July 22, 2014 | 529-for-500 | Forward |
About Geron Corporation - Common Stock Company overview from Wikipedia
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Company information
Geron, based in Foster City, California, was founded by gerontologist Mary C. West and Michael D. West, now CEO of AgeX Therapeutics. They secured initial venture capital investments in the company from Kleiner Perkins Caufield & Byers and Venrock. The company was incorporated in 1990 and began doing business in 1992. John A. Scarlett was appointed CEO in 2011.
The company's Scientific and Clinical Advisory Board has included Nobel laureates James Watson, Gunter Blobel, and Carol Greider, and Leonard Hayflick, known for discovering that human cells divide for a limited number of times in vitro (called the Hayflick limit).
In 2017, Geron staff received the highest median pay in California, at $500,250.
Drug candidates
Cancer therapies
Geron Corporation has sponsored human clinical trials of several potential anti-cancer products.
Imetelstat (GRN163L) is a drug that targets telomerase. In studies conducted at Johns Hopkins University, GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. Similarly, GRN163L inhibited the in vitro clonogenic growth of CD138neg Multiple Myeloma Cancer Stem Cells isolated from the bone marrow aspirates of patients with multiple myeloma. On November 3, 2014, the FDA removed the full clinical hold on imetelstat and declared the company's clinical development plan as acceptable. In 2014, Geron licensed imetelstat to Janssen Biotech. In 2017, imetelstat was granted fast track status by the FDA for certain patients with myelodysplastic syndrome. In 2018, Janssen Biotech returned the rights to imetelstat to Geron. Imetelstat is currently in two Phase 3 trials: NCT02598661, a study of the drug's ability to reduce the transfusion requirements of patients with myelodysplastic syndrome (MDS), and NCT04576156, an investigation of the drug's effect on the overall survival of patients with myelofibrosis.
A trial of GRNVAC1, a telomerase vaccine being used on patients with prostate cancer was carried out at Duke University. Geron's progress with telomerase vaccines attracted a modest monetary investment in 2005 from Merck.
GRN1005, an LRP-directed conjugate of paclitaxel, was in phase II clinical trials for brain cancer but discontinued based on preliminary results in 2012.
Telomerase activation
In addition to testing drug candidates that exploit cancer cell's dependence on telomerase, Geron is researching the possible applications of activating the enzyme in normal cells to delay cellular senescence. The company is in the early stages of developing a telomerase based treatment for HIV called TAT0002, which is the saponin cycloastragenol in Chinese herb Astragalus propinquus. Geron has granted a license to Telomerase Activation Sciences to sell TA-65, the telomerase activator agent also derived from astragalus. In October 2010 Intertek/AAC Labs, an ISO 17025 internationally recognized lab, found the largest component of TA-65 to be cycloastragenol.
Geron originally investigated telomerase as a means of understanding and modifying human aging. However, Geron has ceased aging research of any kind.
Stem cell therapies
On January 23, 2009, Geron received FDA approval to begin Phase I testing of GRNOPC1 in humans. GRNOPC1 is an embryonic stem cell based drug that is designed to treat specific forms of spinal cord injury through remyelination of damaged axons. This trial does not involve direct use of stem cells however, as GRNOPC1 is composed of oligodendrocyte progenitor cells derived from embryonic stem cell lines. Studies have shown significant restoration of mobility in animals with spinal injuries that received cells.
Geron also has several other embryonic stem cell treatments that are still in the preclinical phase, including GRNCM1, a treatment for heart disease, and GRNIC1, a treatment for diabetes. In tests with diabetic mice, 80% of the mice given GRNIC1 were still alive in 50 days while the entire control group, which was given no treatment, perished.
Geron sold its human stem cell research assets to Asterias in 2013.
GRNOPC1
As of October 2010 and November 2010, one of Geron's most highly publicized trial therapy products has been GRNOPC1, a stem cell therapy designed to heal severe spinal cord injuries. The cells in the GRNOPC1 therapy have been coaxed into becoming early myelinated glial cells, a type of cell that insulates nerve cells. For every GRNOPC1 cell that is injected in the patient, they become six to ten cells in a few months.
In October 2011 updated results on four patients were released. The trial was discontinued in Nov 2011.
In early 2013 BioTime, whose CEO at the time was Geron founder Michael D. West, acquired 400 patents and other intellectual property related to embryonic stem cells from Geron and later went on to restart the trial.
Patent issues
Geron Corporation initially held exclusive rights to three cell types derived from embryonic stem cells, as the result of paying for the research originally conducted by Dr. James Thomson at the University of Wisconsin–Madison. The patents on the other three cell types are owned by the Wisconsin Alumni Research Foundation (WARF). WARF and Geron did not charge academics to study human stem cells but did charge commercial users. In 2001 WARF came under public pressure to widen access to human stem-cell technology, and they launched legal action against Geron Corporation to recover some of the previously sold rights. The two sides agreed that Geron would keep the rights to only three cell types.
In October 2006, a legal challenge was mounted to overturn these patents by The Foundation for Taxpayer and Consumer Rights and the non-profit patent-watchdog Public Patent Foundation. They contended that two of the patents granted to WARF are invalid because they cover a technique published in 1992 for which a patent had already been granted to an Australian researcher. Another part of the challenge came from the molecular biologist Jeanne Loring who stated that University of Wisconsin–Madison stem cell pioneer James Thomson's techniques (currently patents held by WARF) are rendered obvious by a 1990 paper and two textbooks. The outcome of this legal challenge was particularly relevant to the Geron Corporation as it can only license patents that are upheld. The patents were ultimately upheld when the reexamination concluded in 2008.
As an interim measure, on January 23, 2007, WARF relaxed the stem cell patents, allowing industry-sponsored research at academic and non-profit institutions without a license. WARF will allow easier and simpler cost free cell transfers among researchers and would not require a license or agreement from California's taxpayer-funded stem cell research program.
Politics
As a participant in the then-controversial stem cell and cloning area, Geron Corporation was asked to testify about its technology before the U.S. Congress. In 2001, when Congress was attempting to ban all forms of cloning, then Geron CEO Thomas Okarma spoke before Congress to preserve cloning for therapeutic purposes.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | GERN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -0.05Y avg ≈-8.0 | ≈-8.0 | · | · | |
| P/S | 0.05Y avg ≈1359.4 | ≈1359.4 | 8.0 | Undervalued | |
| P/B (MRQ) | 0.05Y avg ≈6.2 | ≈6.2 | 2.7 | Undervalued | |
| EV / EBITDA | -0.65Y avg ≈-8.4 | ≈-8.4 | · | · | |
| Price / Cash Flow | -0.05Y avg ≈-7.2 | ≈-7.2 | · | · | |
| EV / Revenue | 0.35Y avg ≈1370.0 | ≈1370.0 | · | · | |
| Price / Tangible Book | 0.05Y avg ≈6.2 | ≈6.2 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | GERN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -14.3%5Y avg ≈-45.5% | ≈-45.5% | -33.0% | Top tier | |
| ROE | -34.4%5Y avg ≈-79.6% | ≈-79.6% | -39.4% | In line | |
| ROIC | -19.9% | · | -34.7% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | GERN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.55Y avg ≈0.5 | ≈0.5 | · | · | |
| Current Ratio (MRQ) | 6.95Y avg ≈4.0 | ≈4.0 | 8.9 | Low liquidity | |
| Quick Ratio | 1.05Y avg ≈0.9 | ≈0.9 | 7.6 | Low liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.55Y avg ≈0.4 | ≈0.4 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | GERN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -60.2%5Y avg ≈111.0% | ≈111.0% | · | · | |
| Revenue CAGR 3Y | -2.1% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | GERN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue / Employee | ≈$918.60 | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 6, 2026 | $-0.02 | $-0.01 | — |
| March 31, 2026 | $-0.01 | $-0.02 | 52.6% | |
| Dec. 31, 2025 | $-0.02 | $-0.03 | 38.1% | |
| Sept. 30, 2025 | $-0.03 | $-0.03 | 11.0% | |
| June 30, 2025 | $-0.02 | $-0.03 | 35.7% | |
| March 31, 2025 | $-0.03 | $-0.04 | 22.3% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $237.0K | $596.0K | $1M | $253.0K | $460.0K | $1M | $1M | $6M | $36M | $1M | |
| SG&A Expense | $159M | $146M | $69M | $44M | $30M | $26M | $21M | $19M | $19M | $19M | $18M | $17M | |
| Operating Expenses | $252M | $251M | $194M | $139M | $115M | $77M | $73M | $32M | $30M | $37M | $37M | $37M | |
| Operating Income | $-69M | $-174M | $-194M | $-139M | $-114M | $-77M | $-73M | $-31M | $-29M | $-31M | $-559.0K | $-36M | |
| Interest Expense | · | $19M | $8M | $7M | $4M | $760.0K | · | · | · | · | · | · | |
| Interest Income | $18M | $20M | $18M | $3M | $527.0K | $2M | $4M | $3M | · | · | · | · | |
| Other Non-op | $-375.0K | $-236.0K | $-23.0K | $1M | $1M | $168.0K | $-69.0K | $-114.0K | · | · | · | · | |
| Pretax Income | $-83M | $-175M | $-182M | $-142M | · | · | · | · | · | · | · | · | |
| Income Tax | $75.0K | $449.0K | $22.0K | · | · | · | · | · | · | · | · | · | |
| Net Income | $-84M | $-175M | $-184M | $-142M | $-116M | $-76M | $-69M | $-27M | $-28M | $-30M | $46.0K | $-36M | |
| EPS (Basic) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 | $-0.28 | · | · | $-0.18 | $-0.19 | $0.00 | $-0.23 | |
| EPS (Diluted) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 | $-0.28 | · | · | $-0.18 | $-0.19 | $0.00 | $-0.23 | |
| Shares (Basic) | 666,662,989 | 646,033,247 | 570,645,405 | 380,784,846 | 327,631,814 | 271,460,265 | · | · | 159,224,986 | 159,045,644 | 158,036,162 | 153,540,341 | |
| Shares (Diluted) | 666,662,989 | 646,033,247 | 570,645,405 | 380,784,846 | 327,631,814 | 271,460,265 | · | · | 159,224,986 | 159,045,644 | 162,663,894 | 153,540,341 | |
| EBITDA | $-69M | $-174M | $-194M | $-139M | $-114M | $-77M | $-73M | $-31M | $-29M | $-31M | $-559.0K | $-36M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $78M | $79M | $70M | $57M | $35M | $10M | $14M | $11M | $16M | $13M | $21M | $43M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $78M | $102M | $93M | $109M | |
| Receivables | $37M | $36M | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $117M | $39M | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $5M | $5M | $5M | $4M | $1M | $2M | $1M | $1M | $580.0K | $524.0K | $647.0K | $736.0K | |
| Current Assets | $520M | $491M | $341M | $180M | $187M | $200M | $142M | $166M | $96M | $116M | $116M | $153M | |
| PP&E (Net) | $884.0K | $1M | $1M | $793.0K | $650.0K | $658.0K | $408.0K | $59.0K | $102.0K | $183.0K | $207.0K | $173.0K | |
| PP&E (Gross) | $3M | $3M | $2M | $2M | $1M | $1M | $1M | $838.0K | $822.0K | $1M | $1M | $1M | |
| Accum. Depreciation | $2M | $2M | $1M | $896.0K | $650.0K | $613.0K | $843.0K | $779.0K | $720.0K | $1M | $1M | $1M | |
| Other Non-current Assets | · | · | · | · | · | · | · | $585.0K | · | · | · | · | |
| Total Assets | $571M | $594M | $394M | $191M | $226M | $271M | $166M | $185M | $110M | $130M | $149M | $173M | |
| Accounts Payable | $11M | $9M | $6M | $10M | $7M | $7M | $1M | $982.0K | $503.0K | $225.0K | $160.0K | $1M | |
| Accrued Liabilities | $51M | $36M | $40M | $33M | $30M | $15M | $8M | $1M | $926.0K | $1M | $1M | $2M | |
| Current Liabilities | $112M | $88M | $108M | $77M | $46M | $31M | $28M | $8M | $7M | $8M | $7M | $42M | |
| Capital Leases | $1M | $2M | $3M | $4M | $4M | $5M | $2M | · | · | · | · | · | |
| Total Liabilities | $345M | $313M | $146M | $111M | $100M | $60M | $30M | · | · | · | · | · | |
| Long-term Debt | · | · | $82M | $51M | · | · | · | · | · | · | · | · | |
| Total Debt | $120M | $118M | $82M | $51M | $50M | $24M | · | · | · | · | · | · | |
| Common Stock | $640.0K | $606.0K | $545.0K | $390.0K | $324.0K | $310.0K | $200.0K | $186.0K | $160.0K | $159.0K | $159.0K | $157.0K | |
| Retained Earnings | $-1.86B | $-1.77B | $-1.60B | $-1.41B | $-1.27B | $-1.16B | $-1.08B | $-1.01B | $-986M | $-958M | $-928M | $-928M | |
| AOCI | $269.0K | $261.0K | $185.0K | $-219.0K | $-173.0K | $78.0K | $132.0K | $-183.0K | $-207.0K | $-53.0K | $-213.0K | $-84.0K | |
| Stockholders' Equity | $226M | $280M | $248M | $80M | $126M | $211M | $135M | $178M | $104M | $122M | $142M | $131M | |
| Liabilities + Equity | $571M | $594M | $394M | $191M | $226M | $271M | $166M | $185M | $110M | $130M | $149M | $173M | |
| Shares Outstanding | 639,856 | 606,388,000 | 544,912,215 | 390,262,524 | 323,731,591 | 310,566,853 | 199,814,581 | 186,392,682 | 159,877,239 | 159,158,636 | 158,781,359 | 157,429,871 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $474.0K | $546.0K | $442.0K | $288.0K | $215.0K | $158.0K | $64.0K | · | · | · | · | · | |
| Stock-based Comp | $27M | $31M | $19M | $8M | $8M | $7M | $6M | $6M | $8M | $8M | $8M | $8M | |
| Restructuring | $17M | $0 | $0 | · | · | · | · | · | · | · | $1M | · | |
| Operating Cash Flow | $-111M | $-219M | $-168M | $-127M | $-96M | $-67M | $-44M | $-21M | $-21M | $-18M | $-24M | $9M | |
| CapEx | · | $680.0K | $830.0K | $431.0K | $207.0K | $401.0K | $413.0K | $16.0K | · | $57.0K | $90.0K | $131.0K | |
| Investing Cash Flow | $107M | $-106M | $-180M | $62M | $72M | $-105M | $27M | $-78M | $23M | $9M | $73.0K | · | |
| Debt Issued | $0 | $121M | $30M | · | $25M | $24M | · | · | · | · | · | · | |
| Net Debt Issued | $0 | $35M | $30M | · | $25M | $24M | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $20M | $4M | $19M | $86M | $1M | $1M | $3M | $98M | |
| Net Stock Activity | · | · | · | · | $20M | $4M | $19M | $86M | $1M | $1M | $3M | $98M | |
| Dividends Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Financing Cash Flow | $2M | $334M | $362M | $87M | $49M | $168M | $19M | $93M | $1M | $1M | $3M | · | |
| Net Change in Cash | $-1M | $10M | $14M | $22M | $25M | · | · | · | $4M | $-8M | $-22M | · | |
| Free Cash Flow | · | $-219M | $-169M | $-128M | $-96M | $-67M | $-44M | $-21M | · | $-18M | $-24M | $9M | |
| Levered FCF | · | $-238M | · | · | · | · | · | · | · | · | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -81832.9% | -23246.6% | -8183.7% | -30400.4% | -15762.0% | -2914.9% | -2746.9% | -497.3% | -1.5% | · | |
| Net Margin | · | · | -77690.7% | -23808.9% | -8335.4% | -29888.1% | -14901.7% | -2534.4% | -2621.2% | -479.3% | 0.13% | · | |
| EBITDA Margin | · | · | -81832.9% | -23246.6% | -8183.7% | -30400.4% | -15762.0% | -2914.9% | -2746.9% | -497.3% | -1.5% | · | |
| ROA | -14.3% | -35.3% | -63.0% | -68.1% | -46.8% | -34.7% | -39.1% | -18.3% | -23.2% | -21.2% | 0.03% | -29.7% | |
| ROE | -34.4% | -61.0% | -68.4% | -150.8% | -83.5% | -34.1% | -47.7% | -15.0% | -24.7% | -22.3% | 0.03% | -37.5% | |
| ROIC | -19.9% | -43.7% | · | · | · | · | · | · | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | 5.6 | 3.2 | 2.4 | 4.1 | 6.5 | 5.0 | 22.0 | 14.7 | 14.8 | 17.5 | 3.7 | |
| Quick Ratio | 1.0 | 1.3 | 0.6 | 0.7 | 0.8 | 0.3 | 0.5 | 1.4 | 14.5 | 14.6 | 17.1 | 3.6 | |
| Debt / Equity | 0.5 | 0.4 | 0.3 | 0.6 | 0.4 | 0.1 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 0.4 | 0.1 | 0.4 | 0.4 | 0.1 | · | · | · | · | · | · | |
| Interest Coverage | · | -9.4 | -23.3 | -20.1 | -30.5 | -101.2 | · | · | · | · | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.35 | $0.46 | $0.46 | $0.20 | $0.39 | $0.68 | $0.68 | $0.95 | $0.65 | $0.77 | $0.90 | $0.83 | |
| Revenue / Share | · | · | $0.00 | $0.00 | · | · | · | · | $0.01 | $0.04 | $0.22 | · | |
| Cash Flow / Share | $-0.17 | $-0.34 | $-0.29 | $-0.33 | · | · | · | · | $-0.13 | $-0.12 | $-0.15 | · | |
| Cash / Share | $0.12 | $0.13 | $0.13 | $0.15 | $0.11 | $0.03 | $0.07 | $0.06 | $0.10 | $0.08 | $0.13 | $0.27 | |
| EPS (TTM) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 | $-0.28 | · | · | $-0.18 | $-0.19 | $0.00 | $-0.23 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -60.2% | -57.2% | 450.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | · | · | -2.1% | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $164M | $30M | $237.0K | $596.0K | $1M | $253.0K | $460.0K | $1M | $1M | $6M | $36M | $1M | |
| Net Income TTM | $-84M | $-175M | $-184M | $-142M | $-116M | $-76M | $-69M | $-27M | $-28M | $-30M | $46.0K | $-36M | |
| Market Cap | $845M | $2.15B | $1.15B | $944M | $395M | $494M | $272M | $186M | $288M | $329M | $769M | $512M | |
| Enterprise Value | $887M | $2.19B | $1.16B | $939M | $410M | $508M | · | · | · | · | · | · | |
| P/E | -10.2 | -13.1 | -6.6 | -6.5 | -3.5 | -5.7 | · | · | -10.0 | -10.9 | · | -14.1 | |
| P/S | 5.1 | 72.5 | 4851.3 | 1584.6 | 283.5 | 1951.8 | 590.8 | 174.9 | 270.2 | 53.5 | 21.1 | 443.8 | |
| P/B | 3.7 | 7.7 | 4.6 | 11.8 | 3.1 | 2.3 | 2.0 | 1.0 | 2.8 | 2.7 | 5.4 | 3.9 | |
| P / Tangible Book | 3.7 | 7.7 | 4.6 | 11.8 | 3.1 | 2.3 | · | · | · | · | · | · | |
| P / Cash Flow | -7.6 | -9.8 | -6.9 | -7.4 | -4.1 | -7.4 | -6.2 | -8.9 | -14.0 | -17.9 | -31.8 | 54.7 | |
| P / FCF | · | -9.8 | -6.8 | -7.4 | -4.1 | -7.4 | -6.1 | -8.9 | · | -17.9 | -31.6 | 55.5 | |
| EV / EBITDA | -12.9 | -12.6 | -6.0 | -6.8 | -3.6 | -6.6 | · | · | · | · | · | · | |
| EV / FCF | · | -10.0 | -6.9 | -7.3 | -4.3 | -7.6 | · | · | · | · | · | · | |
| EV / Revenue | 5.4 | 73.8 | 4901.6 | 1575.1 | 294.3 | 2007.6 | · | · | · | · | · | · | |
| Dividend Yield | · | · | · | · | · | · | · | · | · | · | 0.00% | 0.00% | |
| Earnings Yield | -9.8% | -7.6% | -15.2% | -15.3% | -28.7% | -17.6% | · | · | -10.0% | -9.2% | 0.00% | -7.1% | |
| Payout Ratio | · | · | · | · | · | · | · | · | · | · | 0.00% | 0.00% | |
| Annual Payout | · | · | · | · | · | · | · | · | · | · | $0 | $0 |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57M | $52M | · | $47M | $49M | $40M | · | $28M | $882.0K | $304.0K | $164.0K | $29.0K | $21.0K | $297.0K | $73.0K | $123.0K | |
| SG&A Expense | $39M | $35M | $42M | $39M | $39M | $40M | $43M | $36M | $39M | $27M | $18M | $16M | $13M | $16M | $7M | $7M | |
| Operating Expenses | $70M | $52M | $74M | $61M | $61M | $56M | $68M | $56M | $70M | $56M | $48M | $52M | $40M | $40M | $28M | $29M | |
| Operating Income | $-12M | $158.0K | $-26M | $-14M | $-12M | $-17M | $-20M | $-28M | $-69M | $-56M | $-48M | $-52M | $-40M | $-40M | $-28M | $-29M | |
| Interest Expense | · | · | · | · | · | · | · | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Interest Income | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $4M | $852.0K | $330.0K | $112.0K | |
| Other Non-op | $-9.0K | $-74.0K | $-70.0K | $-161.0K | $-61.0K | $-83.0K | $-48.0K | $-63.0K | $-63.0K | $-62.0K | $-92.0K | $-11.0K | $39.0K | $-138.0K | $1M | $-56.0K | |
| Net Income | $-17M | $-4M | $-29M | $-18M | $-16M | $-20M | $-25M | $-26M | $-67M | $-55M | $-45M | $-49M | $-38M | $-41M | $-28M | $-30M | |
| EPS (Basic) | $-0.02 | $-0.01 | $-0.05 | $-0.03 | $-0.02 | $-0.03 | $-0.04 | $-0.04 | $-0.10 | $-0.09 | $-0.08 | $-0.09 | $-0.07 | $-0.10 | $-0.07 | $-0.09 | |
| EPS (Diluted) | $-0.02 | $-0.01 | $-0.05 | $-0.03 | $-0.02 | $-0.03 | $-0.04 | $-0.04 | $-0.10 | $-0.09 | $-0.08 | $-0.09 | $-0.07 | $-0.10 | $-0.07 | $-0.09 | |
| Shares (Basic) | 670,696 | 669,375 | · | 667,101,756 | 666,170 | 665,905 | · | 662,158,182 | 653,904,978 | 603,493,451 | 579,508,305 | 547,280,946 | 544,459,004 | 405,237,474 | 403,868,713 | 332,066,889 | |
| Shares (Diluted) | 670,696 | 669,375 | · | 667,101,756 | 666,170 | 665,905 | · | 662,158,182 | 653,904,978 | 603,493,451 | 579,508,305 | 547,280,946 | 544,459,004 | 405,237,474 | 403,868,713 | 332,066,889 | |
| EBITDA | $-12M | $158.0K | · | $-14M | $-12M | $-17M | · | $-28M | $-69M | $-56M | $-48M | $-52M | $-40M | $-40M | $-28M | $-29M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63M | $69M | $78M | $78M | $78M | $84M | $79M | $60M | $117M | $190M | $31M | $57M | $113M | $61M | $76M | $31M | |
| Receivables | $52M | $42M | $37M | $35M | $37M | $31M | $36M | $28M | $874.0K | · | · | · | · | · | · | · | |
| Inventory | $124M | $133M | $117M | $95M | $69M | $56M | $39M | $20M | $774.0K | · | · | · | · | · | · | · | |
| Prepaid Expense | $6M | $7M | $5M | $7M | $7M | $7M | $5M | $6M | $6M | $6M | $6M | $4M | $4M | $5M | $3M | $4M | |
| Current Assets | $486M | $499M | $520M | $522M | $506M | $496M | $491M | $398M | $373M | $452M | $335M | $377M | $387M | $222M | $227M | $176M | |
| PP&E (Net) | $1M | $1M | $884.0K | $973.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $733.0K | $641.0K | $643.0K | |
| PP&E (Gross) | · | · | $3M | · | · | · | $3M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $2M | · | · | · | $2M | · | · | · | · | · | · | · | · | · | |
| Total Assets | $519M | $534M | $571M | $567M | $555M | $562M | $594M | $445M | $449M | $482M | $413M | $415M | $425M | $233M | $238M | $198M | |
| Accounts Payable | $9M | $13M | $11M | $11M | $8M | $8M | $9M | $14M | $6M | $10M | $14M | $8M | $3M | $8M | $5M | $6M | |
| Accrued Liabilities | $31M | $31M | $51M | $40M | $26M | $29M | $36M | $36M | $39M | $34M | $42M | $45M | $35M | $53M | $31M | $36M | |
| Current Liabilities | $70M | $74M | $112M | $88M | $64M | $63M | $88M | $138M | $104M | $123M | $89M | $73M | $44M | $83M | $47M | $47M | |
| Capital Leases | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | |
| Total Liabilities | $300M | $305M | $345M | · | · | · | $313M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | $84M | $83M | $83M | $52M | $52M | $51M | $51M | $50M | · | |
| Total Debt | $120M | $120M | · | $119M | $119M | $119M | · | $84M | $83M | $83M | $52M | $52M | $51M | $51M | $50M | $50M | |
| Common Stock | $642.0K | $641.0K | $640.0K | $638.0K | $638.0K | $637.0K | $606.0K | $603.0K | $601.0K | $591.0K | $542.0K | $522.0K | $509.0K | $382.0K | $378.0K | $324.0K | |
| Retained Earnings | $-1.88B | $-1.86B | $-1.86B | $-1.83B | $-1.81B | $-1.79B | $-1.77B | $-1.75B | $-1.72B | $-1.65B | $-1.55B | $-1.50B | $-1.45B | $-1.37B | $-1.33B | $-1.30B | |
| AOCI | $-339.0K | $-191.0K | $269.0K | $408.0K | $117.0K | $304.0K | $261.0K | $1M | $-537.0K | $-273.0K | $-950.0K | $-945.0K | $-160.0K | $-620.0K | $-782.0K | $-711.0K | |
| Stockholders' Equity | $219M | $229M | $226M | $249M | $260M | $268M | $280M | $292M | $307M | $345M | $291M | $298M | $326M | $108M | $142M | $97M | |
| Liabilities + Equity | $519M | $534M | $571M | $567M | $555M | $562M | $594M | $445M | $449M | $482M | $413M | $415M | $425M | $233M | $238M | $198M | |
| Shares Outstanding | 642,470 | 641,033,000 | 639,856,222 | 638,355,275 | 637,849,739 | 636,917,758 | 606,387,666 | 603,102,073 | 601,048,108 | 591,163,808 | 542,479,666 | 521,942,104 | 508,731,846 | 381,214,326 | 377,664,759 | 323,736,875 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $136.0K | $134.0K | $87.0K | $128.0K | $128.0K | $131.0K | $142.0K | $31.0K | $262.0K | $111.0K | $108.0K | $121.0K | $99.0K | $79.0K | $72.0K | $57.0K | |
| Stock-based Comp | $5M | $5M | $6M | $7M | $7M | $7M | $7M | $7M | $13M | $5M | $7M | $4M | $3M | $2M | $2M | $2M | |
| Restructuring | $-157.0K | $-394.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-16M | $-63M | $-22M | $-14M | $-27M | $-48M | $-44M | $-59M | $-53M | $-62M | $-51M | $-30M | $-46M | $-30M | $-29M | $-34M | |
| CapEx | · | · | · | · | · | · | · | $0 | $206.0K | $615.0K | $192.0K | $202.0K | $372.0K | $171.0K | $70.0K | $50.0K | |
| Investing Cash Flow | $8M | $52M | $21M | $13M | $20M | $52M | $-104M | $-554.0K | $-36M | $34M | $-5M | $-44M | $-179M | $10M | $3M | $30M | |
| Financing Cash Flow | $1M | $2M | $378.0K | $542.0K | $1M | $256.0K | $166M | $4M | $17M | $148M | $29M | $18M | $281M | $5M | · | · | |
| Net Change in Cash | $-6M | $-9M | $-553.0K | $389.0K | $-6M | $5M | $19M | $-56M | $-73M | $120M | $-26M | $-56M | $56M | $-15M | $45M | $-4M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-63M | · | · | $-47M | · | · | $-34M |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -21.7% | 0.30% | · | -29.4% | -25.4% | -42.2% | · | -99.8% | -7860.9% | -18465.1% | -29031.7% | -179141.4% | -190914.3% | -13450.5% | -38323.3% | -23313.0% | |
| Net Margin | -29.0% | -7.0% | · | -39.0% | -33.4% | -50.1% | · | -93.5% | -7639.8% | -18220.4% | -27320.1% | -169748.3% | -181533.3% | -13821.9% | -38516.4% | -24469.9% | |
| EBITDA Margin | -21.7% | 0.30% | · | -29.4% | -25.4% | -42.2% | · | -99.8% | -7860.9% | -18465.1% | -29031.7% | -179141.4% | -190914.3% | -13450.5% | -38323.3% | -23313.0% | |
| ROA | -3.1% | -0.66% | · | -3.6% | -3.3% | -3.8% | · | -6.2% | -15.6% | -12.2% | -13.9% | -15.1% | -12.2% | -17.8% | -11.5% | -13.2% | |
| ROE | -7.0% | -1.5% | · | -6.8% | -5.8% | -6.5% | · | -9.1% | -22.3% | -16.5% | -22.5% | -22.4% | -18.0% | -31.6% | -17.7% | -20.2% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.9 | 6.8 | · | 6.0 | 7.9 | 7.9 | · | 2.9 | 3.6 | 3.7 | 3.7 | 5.2 | 8.8 | 2.7 | 4.9 | 3.8 | |
| Quick Ratio | 1.6 | 1.5 | · | 1.3 | 1.8 | 1.8 | · | 0.6 | 1.1 | 1.5 | 0.3 | 0.8 | 2.6 | 0.7 | 1.6 | 0.7 | |
| Debt / Equity | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.5 | 0.4 | 0.5 | |
| LT Debt / Equity | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.2 | 0.3 | 0.3 | 0.5 | |
| Interest Coverage | · | · | · | · | · | · | · | -9.3 | -20.9 | -16.4 | -23.0 | -25.9 | -20.9 | -22.0 | -17.7 | -19.4 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Receivables Turnover | 1.3 | 1.4 | · | 1.5 | 2.6 | 2.5 | · | 2.0 | 2.0 | · | · | · | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $340.27 | $0.36 | · | $0.39 | $0.41 | $0.42 | · | $0.48 | $0.51 | $0.58 | $0.54 | $0.57 | $0.64 | $0.28 | $0.38 | $0.30 | |
| Revenue / Share | $85.70 | $77.44 | · | $0.07 | $0.07 | $0.06 | · | $0.04 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | · | |
| Cash Flow / Share | · | $-93.98 | · | · | · | $-0.07 | · | · | · | $-0.10 | · | · | $-0.09 | · | · | · | |
| Cash / Share | $97.50 | $0.11 | · | $0.12 | $0.12 | $0.13 | · | $0.10 | $0.19 | $0.32 | $0.06 | $0.11 | $0.22 | $0.16 | $0.20 | $0.10 | |
| EPS (TTM) | $-0.11 | $-0.11 | · | $-0.12 | $-0.13 | $-0.21 | · | $-0.31 | $-0.35 | $-0.34 | $-0.35 | $-0.37 | $-0.35 | $-0.35 | $-0.33 | $-0.35 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | $1M | $1M | |
| Net Income TTM | $-68M | $-67M | · | $-80M | $-88M | $-139M | · | $-201M | $-220M | $-201M | $-175M | $-171M | $-150M | $-131M | $-117M | $-118M | |
| Market Cap | $822.4K | $955M | · | $875M | $899M | $1.01B | · | $2.74B | $2.55B | $1.95B | $1.15B | $1.68B | $1.10B | $892M | $585M | $440M | |
| Enterprise Value | $58M | $1.01B | · | $916M | $941M | $1.05B | · | $2.76B | $2.51B | $1.84B | $1.17B | $1.67B | $1.04B | $882M | $560M | $459M | |
| P/E | -11.6 | -13.5 | · | -11.4 | -10.8 | -7.6 | · | -14.6 | -12.1 | -9.7 | -6.1 | -8.7 | -6.2 | -6.7 | -4.7 | -3.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 581.9 | 435.2 | 319.3 | |
| P/B | 0.0 | 4.2 | · | 3.5 | 3.5 | 3.8 | · | 9.4 | 8.3 | 5.7 | 4.0 | 5.6 | 3.4 | 8.2 | 4.1 | 4.5 | |
| P / Tangible Book | 0.0 | 4.2 | · | 3.5 | 3.5 | 3.8 | · | 9.4 | 8.3 | 5.7 | 4.0 | 5.6 | 3.4 | 8.2 | 4.1 | 4.5 | |
| P / Cash Flow | · | -15.2 | · | · | · | -21.1 | · | · | · | -31.3 | · | · | -23.8 | · | · | -13.0 | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | 575.1 | 416.2 | 332.9 | |
| Earnings Yield | -8.6% | -7.4% | · | -8.8% | -9.2% | -13.2% | · | -6.8% | -8.2% | -10.3% | -16.5% | -11.5% | -16.1% | -15.0% | -21.3% | -25.7% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | · | · | $237.0K | $596.0K | $1M |
| Operating Margin % | · | · | -81832.9% | -23246.6% | -8183.7% |
| Net Income | $-84M | $-175M | $-184M | $-142M | $-116M |
| Diluted EPS | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | 0.5 | 0.4 | 0.3 | 0.6 | 0.4 |
| Current Ratio | 4.7 | 5.6 | 3.2 | 2.4 | 4.1 |
| Quick Ratio | 1.0 | 1.3 | 0.6 | 0.7 | 0.8 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | · | $-219M | $-169M | $-128M | $-96M |
Institutional owners (13F) 275 filers · $662.3M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 37 (0 vs prior Q) | 29 (-7 vs prior Q) | 94 (+1 vs prior Q) | 65 (+6 vs prior Q) | -21.3M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $62,867,932 | 49,115,571 | 9.49% | Shares |
| RA CAPITAL MANAGEMENT, L.P. | $54,796,481 | 42,809,751 | 8.27% | Shares |
| Soleus Capital Management, L.P. | $54,795,084 | 42,808,659 | 8.27% | Shares |
| VANGUARD GROUP INC | $47,072,479 | 35,660,969 | 7.11% | Shares |
| STATE STREET CORP | $45,896,539 | 35,856,671 | 6.93% | Shares |
| CITADEL ADVISORS LLC | $37,169,828 | 29,038,928 | 5.61% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $34,880,275 | 27,250,215 | 5.27% | Shares |
| Clearbridge Investments, LLC | $25,150,531 | 19,648,853 | 3.80% | Shares |
| Eversept Partners, LP | $23,958,300 | 18,717,422 | 3.62% | Shares |
| GOLDMAN SACHS GROUP INC | $21,290,712 | 16,633,368 | 3.21% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $18,635,455 | 14,555,954 | 2.81% | Shares |
| MORGAN STANLEY | $16,570,152 | 12,945,431 | 2.50% | Shares |
| Nantahala Capital Management, LLC | $15,648,000 | 12,225,000 | 2.36% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13,840,125 | 10,812,598 | 2.09% | Shares |
| Vivo Capital, LLC | $11,099,900 | 8,671,797 | 1.68% | Shares |
| MILLENNIUM MANAGEMENT LLC | $10,383,702 | 8,112,267 | 1.57% | Shares |
| Kynam Capital Management, LP | $8,750,487 | 6,836,318 | 1.32% | Shares |
| Candriam S.C.A. | $7,147,270 | 5,589,182 | 1.08% | Shares |
| FMR LLC | $7,043,593 | 5,502,807 | 1.06% | Shares |
| Pale Fire Capital SE | $6,793,221 | 5,307,204 | 1.03% | Shares |
| NORTHERN TRUST CORP | $6,441,232 | 5,032,212 | 0.97% | Shares |
| UBS Group AG | $6,267,002 | 4,896,096 | 0.95% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $5,861,120 | 4,579,000 | 0.88% | Shares |
| SEGALL BRYANT & HAMILL, LLC | $5,741,509 | 4,485,554 | 0.87% | Shares |
| TWO SIGMA INVESTMENTS, LP | $5,514,257 | 4,308,013 | 0.83% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $5,484,367 | 4,284,662 | 0.83% | Shares |
| TORONTO DOMINION BANK | $5,420,800 | 4,235,000 | 0.82% | Shares |
| Point72 Asset Management, L.P. | $5,177,857 | 4,045,201 | 0.78% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $5,073,361 | 3,963,563 | 0.77% | Shares |
| BANK OF AMERICA CORP /DE/ | $4,523,820 | 3,534,234 | 0.68% | Shares |
| DEUTSCHE BANK AG\ | $4,403,170 | 3,439,976 | 0.66% | Shares |
| Qube Research & Technologies Ltd | $4,302,828 | 3,361,584 | 0.65% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $3,762,520 | 2,939,469 | 0.57% | Shares |
| JANUS HENDERSON GROUP PLC | $3,303,915 | 2,218,196 | 0.50% | Shares |
| ExodusPoint Capital Management, LP | $3,233,466 | 2,526,145 | 0.49% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $3,093,044 | 2,416,441 | 0.47% | Shares |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $2,982,400 | 2,330,000 | 0.45% | Shares |
| NAN FUNG TRINITY (HK) LTD | $2,846,144 | 2,223,550 | 0.43% | Shares |
| Bank of New York Mellon Corp | $2,071,354 | 1,618,246 | 0.31% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,980,466 | 1,547,239 | 0.30% | Shares |
| Nuveen, LLC | $1,979,489 | 1,546,476 | 0.30% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $1,893,811 | 1,271,014 | 0.29% | Shares |
| World Investment Advisors | $1,540,331 | 1,033,779 | 0.23% | Shares |
| MOORE CAPITAL MANAGEMENT, LP | $1,525,684 | 1,191,941 | 0.23% | Shares |
| Invesco Ltd. | $1,504,266 | 1,175,208 | 0.23% | Shares |
| Kodai Capital Management LP | $1,420,015 | 893,091 | 0.21% | Shares |
| Seven Fleet Capital Management LP | $1,353,252 | 1,057,228 | 0.20% | Shares |
| Virtus Investment Advisers, LLC | $1,294,337 | 1,011,201 | 0.20% | Shares |
| Voleon Capital Management LP | $1,286,385 | 1,004,988 | 0.19% | Shares |
| Swiss National Bank | $1,233,920 | 964,000 | 0.19% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Feb. 3, 2023 | · | Initial filing | · | SEC | |
| Growth Equity Opportunities 17, LLC, New Enterprise Associates 17, L.P., NEA Partners 17, L.P., NEA 17 GP, LLC, Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Liza Landsman, Mohamad H. Makhzoumi, Joshua Makower, Edward T. Mathers, Scott D. Sandell, Peter W. Sonsini, Paul Walker, Rick Yang | June 4, 2020 | · | Initial filing | Passive investment | SEC |
| G ERON C ORPORATION ×3 filings | Aug. 19, 2014 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 49 insiders · 28 officers · 23 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Harout Semerjian | President and CEO | Aug. 7, 2025 A | · | 0 | 0 | $0 |
| John A Scarlett | Chairman, President and CEO | Feb. 27, 2025 P | 12,500 | 0 | 0 | $0 |
| David Greenwood | President, Interim CEO, CFO | June 14, 2011 S | 754,031 | 0 | 0 | $0 |
| Thomas Okarma | President and CEO | July 9, 2010 A | 774,560 | 0 | 0 | $0 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Feb. 18, 2026 M | 17,645 | 0 | 1 | $-19,119 |
| Olivia Kyusuk Bloom | EVP, Chief Financial Officer | Aug. 15, 2023 A | 74,588 | 0 | 0 | $0 |
| Graham K Cooper | EVP, Bus Dev & CFO | May 17, 2012 A | · | 0 | 0 | $0 |
| Alan Colowick | President, Oncology | Jan. 2, 2008 I | 3,028 | 0 | 0 | $0 |
| Andrew J Grethlein | EVP, Chief Operating Officer | Feb. 18, 2025 A | 0 | 0 | 0 | $0 |
| Timothy Williams | EVP and Chief Legal Officer | April 13, 2026 A | · | 0 | 0 | $0 |
| Joseph Eid | EVP, R&D; Chief Medical Office | Feb. 17, 2026 A | · | 0 | 0 | $0 |
| Ahmed Elnawawi | EVP, Chief Commercial Officer | Oct. 20, 2025 A | · | 0 | 0 | $0 |
| James Ziegler | EVP, Chief Commercial Officer | Feb. 27, 2025 P | 100,000 | 0 | 0 | $0 |
| Scott Alan Samuels | EVP, Chief Legal Officer | Feb. 27, 2025 P | 26,682 | 0 | 0 | $0 |
| Faye Feller | EVP, Chief Medical Officer | June 10, 2024 M | 0 | 0 | 0 | $0 |
| Anil Kapur | EVP, Corp Strategy & CCO | June 10, 2024 M | 0 | 0 | 0 | $0 |
| Aleksandra Rizo | EVP, Chief Medical Officer | Feb. 16, 2022 A | · | 0 | 0 | $0 |
| Stephen Rosenfield | EVP, Chief Legal Off & Sec | Feb. 16, 2022 A | 0 | 0 | 0 | $0 |
| Melissa Kelly Behrs | EVP, Chief Business Officer | Feb. 2, 2021 A | 0 | 0 | 0 | $0 |
| Craig C Parker | EVP, Corp Dev & Sci Affairs | Feb. 10, 2014 A | · | 0 | 0 | $0 |
| Stephen Michael Kelsey | EVP, R&D, Chief Med Officer | May 3, 2013 D | 62,272 | 0 | 0 | $0 |
| David Earp | SVP, Corp Transactions | May 30, 2012 S | 467,406 | 0 | 0 | $0 |
| Katharine E. Spink | SVP Alliance Mgmt & Operations | June 14, 2011 S | 328,561 | 0 | 0 | $0 |
| Jane Lebkowski | SVP, Chief Scientific Officer | June 14, 2011 S | 568,154 | 0 | 0 | $0 |
| Melanie I Nallicheri | SVP Corp Dev | May 20, 2011 A | 195,000 | 0 | 0 | $0 |
| Fabio M Benedetti | SVP, Chief Med Off, Oncology | May 29, 2009 A | 80,560 | 0 | 0 | $0 |
| Calvin Harley | VP, CSO Telomerase Tech | May 29, 2009 A | 134,036 | 0 | 0 | $0 |
| William Stempel | VP and General Counsel | May 27, 2004 A | 6,521 | 0 | 0 | $0 |
| Robert J. Spiegel | Director | Sept. 30, 2026 A | 212,161 | 0 | 0 | $0 |
| John F Mcdonald | Director | May 20, 2026 A | · | 0 | 0 | $0 |
| Elizabeth G. O'Farrell | Director | May 20, 2026 A | 26,220 | 0 | 0 | $0 |
| Dawn Carter Bir | Director | May 20, 2026 A | · | 0 | 0 | $0 |
| Susan Molineaux | Director | May 20, 2026 A | 130,527 | 0 | 0 | $0 |
| Constantine Chinoporos | Director | March 25, 2026 A | · | 0 | 0 | $0 |
| Patricia S Andrews | Director | March 25, 2026 A | · | 0 | 0 | $0 |
| Gaurav Aggarwal | Director | May 21, 2025 A | 1,970 | 0 | 0 | $0 |
| Bryan V Lawlis | Director | May 21, 2025 A | 13,300 | 0 | 0 | $0 |
| Karin Eastham | Director | Jan. 13, 2023 M | 109,047 | 0 | 0 | $0 |
| Daniel Bradbury | Director | March 29, 2019 A | 51,323 | 0 | 0 | $0 |
| Hoyoung Huh | Director | May 15, 2018 A | 154,301 | 0 | 0 | $0 |
| Thomas Hofstaetter | Director | March 18, 2015 M | 26,564 | 0 | 0 | $0 |
| Thomas Kiley | Director | May 22, 2013 D | 171,911 | 0 | 0 | $0 |
| Edward V Fritzky | Director | May 22, 2013 D | 186,511 | 0 | 0 | $0 |
| Alexander E Barkas | Director | May 20, 2011 A | 353,122 | 0 | 0 | $0 |
| Charles J Homcy | Director | May 11, 2011 A | 62,751 | 0 | 0 | $0 |
| ZENNER PATRICK J | Director | May 19, 2010 A | 73,710 | 0 | 0 | $0 |
| John Peter Walker | Director | Jan. 30, 2009 M | 39,119 | 0 | 0 | $0 |
| Robert B Stein | Director | Sept. 23, 2003 M | 0 | 0 | 0 | $0 |
| MERIX BIOSCIENCE INC | 10% owner | Aug. 16, 2004 S | 4,541,100 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 24 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1.54% | 1,180,129 NS | July 31, 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.43% | 80,446 SH | Oct. 1, 2026 | Daily |
| LABU · Direxion Shares ETF Trust | 0.19% | 741,331 NS | July 31, 2026 | N-PORT |
| ESSC · Strategy Shares | 0.13% | 35,108 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.06% | 4,783,606 SH | Sept. 11, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.05% | 10,128 NS | July 31, 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.05% | 45,101 SH | Oct. 1, 2026 | Daily |
| IWO · iShares Trust | 0.05% | 5,238,232 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 599,922 SH | Aug. 19, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.03% | 749,628 SH | Oct. 1, 2026 | Daily |
| IWM · iShares Trust | 0.03% | 14,214,009 SH | Sept. 11, 2026 | Daily |
| RSSL · Global X Funds | 0.02% | 267,254 NS | July 31, 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 3,218,859 SH | Aug. 19, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 6,164,114 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 1,437,897 SH | Aug. 19, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 237,415 NS | July 31, 2026 | N-PORT |
| WSML · iShares Trust | 0.01% | 34,308 SH | Sept. 10, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 169,800 SH | Sept. 10, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 725,966 SH | Sept. 11, 2026 | Daily |
| TILT · FlexShares Trust | 0.00% | 3,634 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 20,449,234 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 41,165 SH | Aug. 19, 2026 | Daily |
| ISCB · iShares Trust | · | 21,772 SH | Sept. 11, 2026 | Daily |
| ISCV · iShares Trust | · | 107,848 SH | Sept. 11, 2026 | Daily |
GERN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
4 analysts · 2026-09-28Mean target $4.25 +254.2%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| GERN | $845M | -10.2 | -60.2% | · | -34.4% | · |
| ARDX | $1.42B | -22.4 | 22.1% | -15.1% | -40.2% | · |
| ANNX | $750M | -3.7 | · | · | -100.7% | · |
| AVTX | $336M | -3.1 | -86.6% | -132642.4% | -83.4% | · |
| CADL | $310M | -7.8 | · | · | -53.7% | · |
| DSGN | $567M | -7.7 | · | · | -32.8% | · |
| GYRE | $645M | 353.0 | 10.2% | 8.5% | 11.7% | · |
| FDMT | $432M | -3.1 | 230194.6% | -164.4% | -30.2% | · |
| ACHV | · | -4.0 | · | · | · | · |
| SLDB | $445M | -2.8 | · | · | -79.5% | · |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.